Fredun Pharmaceuticals reports 27% revenue growth in Q4FY26
Fredun Pharmaceuticals reported strong Q4FY26 results with total income growing 27.27% to INR213 crores and net profit rising 56.47% to INR11.07 crores. For FY26, revenue reached INR639.12 crores, up 40.08%. Management highlighted robust growth in new age businesses like pet care and mobility, and provided a top-line growth guidance of 25-30% for FY27.
*this image is generated using AI for illustrative purposes only.
Fredun Pharmaceuticals Limited reported a 27.27% year-on-year increase in total income to INR213 crores for the quarter ended March 31, 2026, driven by strong performance across its new age businesses. Net profit for the quarter surged 56.47% to INR11.07 crores, while EBITDA rose 67.05% to INR29.13 crores, expanding margins by 326 basis points to 13.67%. For the full fiscal year FY26, the company achieved a total income of INR639.12 crores, a growth of 40.08%, with a net profit of INR33.21 crores, up 59.59%.
The financial results were discussed during the Q4FY26 earnings conference call held on June 10, 2026, moderated by Kirin Advisors. Fredun Medhora, Managing Director, highlighted that the company is transitioning from a contract manufacturer to a mass-market consumer product company. He stated that the new age businesses, including pet care and mobility, are growing at a 40% to 50% CAGR with higher gross margins ranging between 45% and 55%.
Financial Performance
| Metric | Q4FY26 | Q4FY25 | YoY Growth |
|---|---|---|---|
| Total Income | INR213 crores | INR167.41 crores | 27.27% |
| EBITDA | INR29.13 crores | - | 67.05% |
| EBITDA Margin | 13.67% | - | 326 bps expansion |
| Net Profit | INR11.07 crores | - | 56.47% |
| Net Profit Margin | 5.19% | - | 97 bps expansion |
| Metric | FY26 | YoY Growth |
|---|---|---|
| Total Income | INR639.12 crores | 40.08% |
| EBITDA | INR94.79 crores | 72.05% |
| Net Profit | INR33.21 crores | 59.59% |
Business Segments and Strategy
Management provided a breakdown of the revenue streams for FY26. The vintage business, growing at 15% to 20%, includes exports of approximately INR120 crores, tolling of INR24 crores, and domestic third-party branding of INR50 crores. The new age businesses contributed significantly, with the pet care business generating INR43 crores in sales and the mobility division recording INR30 crores. The company targets INR100 crores in revenue from the mobility division within 2.5 years.
Fredun Medhora outlined plans to launch hormonal and anti-aging product lines, positioning the company as one of the first to offer medicated hormone products online through the doctor channel. The company is also preparing to launch 'wagr.in', a holistic pet care platform, by early July. Regarding capacity, the company utilizes 43 manufacturing locations, with over 80% of products manufactured in-house.
Guidance and Outlook
The company has provided a growth guidance of 25% to 30% on the top line for FY27. Management indicated that margins are expected to continue improving over the next 8 quarters, potentially reaching a PAT margin of 10% to 12% in the coming years as the demographic reach of new products saturates. The company maintains an order book of INR320 crores to INR330 crores.
Historical Stock Returns for Fredun Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | +6.14% | +9.62% | +64.30% | +229.41% | +560.53% |
What specific marketing strategies will be employed to achieve the targeted INR100 crores revenue for the mobility division within the next 2.5 years?
How will the launch of 'wagr.in' and the entry into hormonal products impact the company's customer acquisition costs in the near term?
What capital expenditures are required to scale the new age businesses, and how might this affect free cash flow over the next fiscal year?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
